Co-Authors
This is a "connection" page, showing publications co-authored by Otavio Berwanger and Sheryl Windsor.
Connection Strength
0.239
-
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 09; 9(9):586-594.
Score: 0.239
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.